scholarly journals Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer

2015 ◽  
Vol 100 (4) ◽  
pp. 1529-1536 ◽  
Author(s):  
Ewa Ruel ◽  
Samantha Thomas ◽  
Michaela Dinan ◽  
Jennifer M. Perkins ◽  
Sanziana A. Roman ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Radioactive Iodine ◽  
Intermediate Risk ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

The Role of Radioactive Iodine Therapy in Young Patients With Papillary Thyroid Cancer

2009 ◽  
Vol 34 (1) ◽  
pp. 4-6 ◽  
Author(s):  
Sheng-Fong Kuo ◽  
Tzu-Chieh Chao ◽  
Hung-Yu Chang ◽  
Chuen Hsueh ◽  
Yu-Chen Chang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Radioactive Iodine ◽  
Young Patients ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

scholarly journals The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER

2018 ◽  
Vol Volume 11 ◽  
pp. 3551-3560 ◽  
Author(s):  
Jianing Tang ◽  
Deguang Kong ◽  
Qiuxia Cui ◽  
Kun Wang ◽  
Dan Zhang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Observational Study ◽  
Papillary Thyroid Cancer ◽  
Radioactive Iodine ◽  
Radioactive Iodine Therapy ◽  
Papillary Thyroid

scholarly journals Is postoperative radioactive iodine associated with a survival advantage among…

2017 ◽  
Vol 8 (1) ◽  
pp. 23-27
Author(s):  
Rasha Hamdy Hamed
Keyword(s):  
Overall Survival ◽  
Thyroid Cancer ◽  
Cancer Patients ◽  
Papillary Thyroid Cancer ◽  
Radioactive Iodine ◽  
Survival Advantage ◽  
Positive Surgical Margin ◽  
Intermediate Risk ◽  
Papillary Thyroid ◽  
Risk Of Death

Abstract Aim This trial aimed to determine wether postoperative radioactive iodine(RAI) associated with a survival benefit among intermediate-risk Papillary Thyroid Cancer patients or not. Methods this study is a retrospective study of intermediate-risk papillary thyroid cancer patients that were treated with or without post operative RAI from 1st January 2002 till 1st January 2012. Overall survival (OS) and multivariate regression analyses were measured for all patients. Results 100 patients were included in this trial : 70 patients received postoperative RAI and 30 patients did not. The mean follow-up time was 7.1 (4.8 -15.1 years), and a median survival time could not be estimated. Overall survival at 10 years was 96% in the RAI vs 93% in the group without RAI (P < .001). RAI reduced risk of death by a 27% [hazard risk (HR) 0.73, confidence interval (CI) 0.64 - 0.84, P < .001]. Older patient age, male gende, larger tumor size, multifocal tumors, lymph node metastases, aggressive histology, vascular invasion, positive surgical margin, minimal extrathyroidal extension and absence of postoperative RAI were accompanied by compromised OS (all P ≤ .001). Conclusion This representative study addresses the survival advantage of RAI for with intermediate risk PTC patients but conducting of large prospective randomized controlled trial is still warranted.

Sign in / Sign up

Export Citation Format

Share Document